grace capital trimmed its position in Nevro Corp (NYSE:NVRO) by 58.8% during the 2nd quarter, Holdings Channel reports. The firm owned 5,263 shares of the medical equipment provider’s stock after selling 7,514 shares during the quarter. grace capital’s holdings in Nevro were worth $420,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of NVRO. BlackRock Inc. grew its position in Nevro by 9.9% in the second quarter. BlackRock Inc. now owns 2,947,118 shares of the medical equipment provider’s stock worth $235,328,000 after acquiring an additional 265,361 shares in the last quarter. Jennison Associates LLC grew its position in Nevro by 22.3% in the second quarter. Jennison Associates LLC now owns 1,690,765 shares of the medical equipment provider’s stock worth $135,008,000 after acquiring an additional 307,980 shares in the last quarter. Wells Fargo & Company MN grew its position in Nevro by 66.0% in the second quarter. Wells Fargo & Company MN now owns 1,366,980 shares of the medical equipment provider’s stock worth $109,153,000 after acquiring an additional 543,401 shares in the last quarter. Zevenbergen Capital Investments LLC grew its position in Nevro by 8.9% in the second quarter. Zevenbergen Capital Investments LLC now owns 667,730 shares of the medical equipment provider’s stock worth $53,318,000 after acquiring an additional 54,430 shares in the last quarter. Finally, Artisan Partners Limited Partnership grew its position in Nevro by 1.6% in the second quarter. Artisan Partners Limited Partnership now owns 596,939 shares of the medical equipment provider’s stock worth $47,666,000 after acquiring an additional 9,152 shares in the last quarter.

Several research firms recently commented on NVRO. ValuEngine lowered Nevro from a “hold” rating to a “sell” rating in a research report on Thursday, May 17th. Leerink Swann dropped their price target on Nevro from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, July 17th. Canaccord Genuity dropped their price target on Nevro from $102.00 to $83.00 and set a “buy” rating for the company in a research report on Monday, July 16th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Nevro in a research report on Wednesday, July 11th. Finally, Morgan Stanley lowered Nevro from an “overweight” rating to an “equal weight” rating and set a $95.00 price target for the company. in a research report on Monday, July 2nd. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $81.89.

Shares of NYSE:NVRO opened at $61.38 on Friday. Nevro Corp has a 1 year low of $35.41 and a 1 year high of $94.34. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -49.10 and a beta of -0.71. The company has a quick ratio of 6.29, a current ratio of 8.06 and a debt-to-equity ratio of 0.61.

Nevro (NYSE:NVRO) last announced its earnings results on Thursday, August 2nd. The medical equipment provider reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.04). Nevro had a negative net margin of 10.68% and a negative return on equity of 15.84%. The business had revenue of $96.10 million for the quarter, compared to analysts’ expectations of $96.10 million. During the same quarter last year, the firm earned ($0.40) EPS. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. analysts anticipate that Nevro Corp will post -1.42 EPS for the current fiscal year.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Further Reading: Understanding Average Daily Trade Volume

Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp (NYSE:NVRO).

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.